| Document |
Document Title |
|
WO/2019/164562A3 |
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal. Such comp...
|
|
WO/2019/210845A1 |
A recombinant human HNP-1 protein. By constructing and using Escherichia coli expression system, a mature human HNP-1 protein having biological activity is prepared. The recombinant human HNP-1 protein has antibacterial activity, i.e., t...
|
|
WO/2019/213528A1 |
Processes for producing recombinant proteins having low levels of residual host cell proteins. The processes comprise utilizing engineered host cell lines in which specific host cell proteins are tagged with purification tags, wherein th...
|
|
WO/2019/213257A1 |
Provided are compositions, systems, and methods useful for effecting gene editing in eukaryotic cells. Compositions include plasmids that encode one or more viral fusion proteins in which one or more viral proteins are fused with an apta...
|
|
WO/2019/211958A1 |
Provided is a method for improving the efficiency of production of an organic compound by a bacterium that does not inherently have an endogenous ED pathway. One embodiment pertains to a transformant of a coryneform bacterium obtained by...
|
|
WO/2019/152876A3 |
Described herein are compositions and methods for identifying, selecting, or culturing cells comprising a subject nucleic acid sequence of interest. Generally, a nucleic acid comprising a subject nucleic acid and a sequence encoding an e...
|
|
WO/2019/213374A1 |
Provided herein are compositions and methods for production of proteins in microbial systems. In particular, provided herein are compositions and methods for expressing exogenous genes from specific chromosomal locations of E. coli. Spec...
|
|
WO/2018/178770A8 |
The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells...
|
|
WO/2019/213434A1 |
The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors compr...
|
|
WO/2019/213128A1 |
Described herein are compositions and methods for treating a disease in a subject by administering delivery vectors that express artificial microRNAs, artificial microRNA clusters, and/or a combination of microRNA clusters and associated...
|
|
WO/2019/211796A1 |
Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch...
|
|
WO/2019/211492A1 |
The invention relates to a composition comprising a double-stranded RNA (dsRNA) having two complementary strands, comprising at least one block of poly A and the complementary block of poly U, each strand having a length of between 50 an...
|
|
WO/2019/212752A1 |
Disclosed herein, are compounds comprising a peptide, wherein the peptide is OCA-B or an OCA-B fragment thereof; a linker; and a cell penetrating peptide. Also described herein, are methods of administering compounds to subjects for the ...
|
|
WO/2019/213527A1 |
Mammalian cell lines genetically engineered to have reduced or eliminated expression of specific host cell proteins, and methods for using the engineered mammalian cell lines for the production of recombinant proteins having low levels o...
|
|
WO/2019/213626A1 |
Disclosed are methods of genomic modification of skeletal and cardiac muscle using sequence-targeting nucleases and a donor sequence delivered via a virus.
|
|
WO/2019/145796A3 |
The present technology relates to gene delivery vehicles comprising a retroviral vector coated with a polymer or a mixture of polymers to form a nanoparticle. The retroviral vectors comprise a transgene and in certain embodiments lack en...
|
|
WO/2019/211401A1 |
The present invention relates to fusion proteins comprising a cell surface marker specific VHH. In particular, the invention relates to bispecific VHH adaptor proteins, i.e. fusion proteins comprising an adeno-associated virus (AAV) spec...
|
|
WO/2019/211854A1 |
The disclosure herein relates to photoinitiated dermal fillers, hyaluronic acid-rhCollagen double crosslinked dermal fillers and hyaluronic acid-rhCollagen semi interpenetrated network, each comprising plant-derived human collagen, as we...
|
|
WO/2019/213504A1 |
The present invention is directed to the filed of gene therapy. In particular, compositions and methods are disclosed that repair gene microduplication mutations by reversion to a wild type sequence. For example, the creation of a double...
|
|
WO/2019/213430A1 |
The disclosure describes that both Cas9 and Cpf1 enzymes can exhibit potent nickase activities on an extensive class of mismatched dsDNA targets. These properties allow the production of efficient nickases for a chosen dsDNA target seque...
|
|
WO/2019/210863A1 |
A genetically engineered cell. The cell expresses an exogenous receptor binding to an antigen, and expresses increased RUNX3 or exogenous RUNX3. Also provided are a use of the cell and a method for treating tumors.
|
|
WO/2019/210606A1 |
Provided are an acid phosphatase mutant, an application thereof, and a method for preparing nicotinamide riboside, wherein the conversion rate is more than 99%.
|
|
WO/2019/211842A1 |
Compositions which include human growth hormone (hGH) antagonist variants, polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus of a human growth hormone (hGH) ant...
|
|
WO/2019/213510A1 |
Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. I...
|
|
WO/2019/213592A1 |
Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.
|
|
WO/2019/213062A1 |
A composition including an isolated cloaked gene editor. A composition for treating a lysogenic virus, including a vector encoding isolated nucleic acid encoding two or more cloaked gene editors chosen from cloaked gene editors that targ...
|
|
WO/2019/210552A1 |
Provided are a neutralizing antibody against tetanus toxins, and a use thereof. The provided neutralizing antibody against tetanus toxins is capable of specifically binding to tetanus toxins, and thus has strong neutralizing activity and...
|
|
WO/2019/212922A1 |
The present disclosure relates to using spectrophotometry to estimate genome copies and full/empty ratios adeno-associated virus particles.
|
|
WO/2019/212973A1 |
Aspects of the disclosure relate to integration of a transgene packaged into recombinant adeno-associated virus (rAAV) by nuclease-assisted vector integration (NAVI).
|
|
WO/2019/210392A1 |
Described herein is a novel method for generation of recombinant poxviruses using an E3 and K3 double deletion mutant virus as the parental virus for generation of recombinant viruses. Following allowing for crossing over between the par...
|
|
WO/2019/190930A3 |
RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1313 and compositions, methods, and uses thereof.
|
|
WO/2019/211296A1 |
The invention pertains to a method for regenerating a plant cell, preferably regenerating a shoot from a plant cell by altering the expression levels of at least WOX5 and a PLT protein, preferably WOX5 and PLT1. In addition the expressio...
|
|
WO/2019/213183A1 |
A method for in utero genome editing, the method comprising administering to a subject an adenoviral vector, wherein the subject is a fetus, the adenoviral vector comprising CRISPR-mediated base editor and a guide RNA (gRNA), the gRNA ta...
|
|
WO/2019/213011A1 |
In one aspect of the instant invention, lentiviral vectors are provided, particularly for treating hemoglobinopathies. Composition comprising the lentiviral vector are also encompassed by the instant invention. In accordance with another...
|
|
WO/2019/190927A3 |
The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-sw...
|
|
WO/2019/161139A3 |
Disclosed are probes based on papilloma virus and modified SV40 that can be used for detecting circulating tumor cells (CTCs) in the blood stream, methods for manufacturing such probes, and methods for using such probes.
|
|
WO/2019/213028A1 |
Methods for increasing carbon-based chemical product yield in an organism by genetically modifying one or more genes involved in a stringent response and/or in a regulatory network, nonnaturally occurring organisms having increased carbo...
|
|
WO/2019/210347A1 |
A method of treating muscular dystrophy in a subject or for improving muscle function or delaying decline in muscle function in a subject with muscular dystrophy comprising administering to the subject a pharmaceutical composition compri...
|
|
WO/2019/213421A1 |
Provided herein are systems, methods, and apparatus for electroporation, which may include an applicator; an endoscope, trocar or the like; a generator; and a drug delivery device. The applicator may include a control portion, an inserti...
|
|
WO/2019/195274A3 |
The present invention provides a recombinant eukaryotic cell expressing one or more heterologous double strand break (DSB) repair proteins in an amount effective for enhancing DSB repair in the cell. The recombinant eukaryotic cell may e...
|
|
WO/2019/213581A1 |
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecul...
|
|
WO/2019/213019A1 |
Methods for increasing carbon-based chemical product yield in an organism by increasing carbon uptake and/or altering a pathway to or from an overflow metabolite in the organism, nonnaturally occurring organisms having increased carbon-b...
|
|
WO/2019/213033A1 |
Methods of redirecting carbon flux and increasing C2/C3 or a C4/5/6 carbon chain length carbon-based chemical product yield in an organism, nonnaturally occurring organisms with redirected carbon flux and increased C2/C3 or C4/5/6 carbon...
|
|
WO/2019/213017A1 |
Methods for increasing carbon-based chemical product yield in an organism by perturbing redox balance in an organism as well as nonnaturally occurring organisms with perturbed redox balance and methods for their use in producing carbon-b...
|
|
WO/2019/186514A3 |
Compositions comprising aptamers, and methods of thereof as carrier molecules in cell-mediated immunotherapies, and activation of antigen-specific T- cell responses.
|
|
WO/2019/212632A1 |
The present disclosure includes methods and compositions for improving leaf quality in low-alkaloid tobacco plants, e.g., by combining inducible promoters and non-coding RNAs for suppression of an ornithine decarboxylase (ODC) gene. Also...
|
|
WO/2019/213668A1 |
Human anti-AAV capsid polyclonal antibody conformational epitopes including those of neutralizing antibodies are provided. The epitopes can be recognized by human anti-AAV2 or other AAV strain-derived capsid polyclonal antibodies. One or...
|
|
WO/2019/211969A1 |
The present invention addresses the issue of providing a modified esterase that can provide high reaction efficiency and is applicable to a variety of applications. Provided is a modified esterase having an amino acid sequence of SEQ ID ...
|
|
WO/2019/213481A1 |
Described herein are methods and compositions for treating inflammatory disease. Aspects of the invention relates to administering to a subject an agent that inhibits RSK1. Another aspect of the invention relates to administering the STA...
|
|
WO/2019/211750A1 |
A coffee plant comprising a genome comprising a loss of function mutation in a nucleic acid sequence encoding at least one component of a caffeine biosynthesis pathway is disclosed. Methods of producing a coffee plant or part thereof, me...
|
